Ichnos Glenmark Innovation’s Post

Did you catch our poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting? See the data that were presented on our lead candidate, nemvaleukin alfa, and view all of our recent publications: https://bit.ly/3KrYlzM #biotechnology #drugdevelopment #ASCO24 #innovation

Interesting perspective on future immunotherapeutics

Our Head of Translational Medicine Kenneth Crook will be presenting Engimmune's AI-guided platform technologies for soluble TCR drug development at Immuno 2024 on April 25-26. In this video, we get his perspective on current trends in immuno-oncology and on how specTR molecules (specificity- and affinity-enhanced soluble TCR engagers) can address key challenges in the treatment of solid tumours. https://lnkd.in/eP7XteCS

Great to see more evidence to support our hypothesis - initially published in Fraser et al, Nature Communications, 2021) that loss of ZNRF3 and WNT activation is a driver of poor outcomes in cancer (now in a pan-cancer context). #genomics #cancergenomics #computationalbiology https://lnkd.in/gtsnrGvg

Missed out on this year's #ASMS conference? That doesn’t mean you have to miss out on the exciting science we shared! Check out this poster presented by Jeremiah Bowers, based on a collaboration with MOMA Therapeutics.      By leveraging cutting-edge proteomic technologies and mass spectrometry workflows developed by Momentum, Bowers and colleagues were able to identify and characterize several covalent cysteine modifiers active against cancer-driving helicases. Their research demonstrates the power of mass spec covalent binding screening, modification mapping, and occupancy calculations in taking a project from screening to hit characterization with unmatched efficiency.      Want to learn more about this project? Request the full poster here: https://lnkd.in/e6GFCEvW      #CancerResearch #DrugDiscovery #RapidFireMS, #OrbitrapAscend #Covalent #Chemoproteomics #Chemicalbiology

The number of ADCs showing promising outcomes in clinical trials is rapidly growing, offering exciting opportunities for cancer patients. The inaugural Engineering Conjugates conference ( https://lnkd.in/egpzyeYZ) at #PEGSEurope brings leaders in the field together to share innovations in next-gen #ADC formats to enhance #payload delivery and improve #therapeuticindex. Hear progress in bispecific ADCs, peptide/fragment-based ADCs, dual-payloads, novel targets such as Nectin-4, CEACAM5C and more! Speakers include: Yves BAUDAT, Sanofi Ulrich Brinkmann, Roche Innovation Center Munich Jutta Deckert, Iksuda Therapeutics Mahendra Deonarain, Antikor Biopharma Nimish Gera, Mythic Therapeutics Kim Holmstrøm, Bioneer AS Ilias Koutsopetras, University of Strasbourg Sara Mangsbo, Uppsala University Diane Retallack, Primrose Bio Min Shan 单旻, Merck KGaA Caroline Soulas, Innate Pharma Philipp Spycher, Araris Biotech Ralf Strasser, Bruker Biosensors Obinna C Ubah, Elasmogen Ltd Sandra Uhlenbroich, Bicycle Therapeutics #proteinengineering #Antibodydrugconjugates #noveltargets

Our DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. https://bit.ly/3xixJIx #Oncology #SolidTumors

Today, let's reminisce about Vyro's participation in the Free Conference, hosted by the Ministry of Science, Technology, and Innovation (MCTI), to discuss the theme "Biotechnology as a Tool for a Fair, Sustainable, and Developed Brazil." ➡️ On this occasion, Norberto Prestes, Executive President of the Brazilian Association of Pharmaceutical Inputs Industries (ABIQUIFI), discussed high-impact investments. To learn more, check out the video! #vyro #cancer #zikavirus #govyro #biotechnology #biotecnologia

Covalent inhibitors have experienced a noticeable resurgence in the drug discovery in recent years. In light of this growing interest in this topic, our scientists have undertaken a study exploring a novel synthetic approach to α-fluorovinyl ketones, aiming to validate their potential as inhibitors of KRAS G12C protein – one of the most notorious oncogenic proteins. The study highlights the potential of this novel covalent warhead, demonstrating that α-fluorovinyl ketones can effectively function as covalent inhibitors by specifically targeting selected cysteine residues within a protein of interest. Discover our scientific poster which was recently showcased at EFMC-ISMC and learn more about the latest breakthroughs in α-fluorovinyl ketones as novel covalent warheads here: http://bit.ly/3ZmUpck Stay updated on more research from Selvita by visiting our website: https://lnkd.in/ejajfn2J #DrugDiscovery #CovalentInhibitors #OncologyResearch #αFluorovinylKetones #KRASG12C #EFMCISMC

Twenty three companies will share from £12 million in funding that has been awarded to advance innovative cancer projects and will be shared by 16 projects led by small and medium-sized enterprises at various stages right from feasibility through to regulatory approval. They include industry-led research and development projects by Antikor Biopharma Ltd, Cell Guidance Systems, Coding Bio, Epitopea, Grey Wolf Therapeutics, Lentitek, Medannex Ltd, Mestag Therapeutics, Momentous Therapeutics Ltd, Pathios Therapeutics, Prokarium, QV Bioelectronics, Revolver Therapeutics, #Sferola, Theolytics, VacV Biotherapeutics Feasibility project by CREASALLIS, Galytx, Kargenera, New Path Molecular Research, #OligoTune, Proteotype Diagnostics & Xgenera Congratulations to you all and we look forward to hearing more about the results Find out more via UK Research and Innovation https://lnkd.in/eg5RsCu8 #CancerResearch #InnovationInHealthcare #SmallBusinessGrants #MedicalInnovation #HealthTech #ClinicalTrials #BiotechFunding #HealthcareInnovation #SMEFunding #ResearchAndDevelopment